Prostate Cancer - KOL Insight

Description

Delve into the evolving landscape of prostate cancer treatment with insights from 12 key opinion leaders. This report explores the future of therapies like Xtandi, Erleada, and Orgovyx, the impact of PARP inhibitors, and the potential of novel treatments. Understand the challenges and opportunities in addressing unmet needs and the role of AI in advancing care.

Key questions answered:

How is the use of Xtandi expected to evolve in the next three to five years?
What is the clinical experience with Erleada, and how significant is its Phase III PROTEUS study?
Can Orgovyx challenge conventional ADTs in clinical practice?
How are PARP inhibitors impacting the treatment paradigm for prostate cancer
What role might immune checkpoint inhibitors play in prostate cancer treatment?
How significant is the approval of Pluvicto for metastatic prostate cancer, and what are its benefits over Xofigo?

Key brands covered in this report:

Xtandi (enzalutamide)
Erleada (apalutamide)
Nubeqa (darolutamide)
Orgovyx (relugolix)
Rubraca (rucaparib)
Lynparza (olaparib)
Akeega (abiraterone acetate/niraparib)
Talzenna (talazoparib)

Saruparib
Tecentriq (atezolizumab)
Keytruda (pembrolizumab)
Xofigo (radium-223 dichloride)
Pluvicto (Lutetium-177 PSMA 617)
[Lu-177]-PNT2002
Truqap (capivasertib)
Verzenio (abemaciclib

Companies:

Novartis
Lilly
Roche
AstraZeneca
Pfizer
Merck & Co.
Genentech
Astellas

Takeda
Bayer
Orion Pharma
Johnson & Johnson
Lantheus
pharma&
Sumitomo Pharma America
POINT Biopharma

Executive summary

Current and future treatment algorithm

Research objectives

Next-generation androgen receptor inhibitors

Marketed drugs
- Xtandi (enzalutamide; Astellas Pharma/Pfizer)
- Erleada (apalutamide; Johnson & Johnson)
- Nubeqa (darolutamide; Bayer/Orion)

Novel formulation androgen-deprivation therapies

Marketed drugs
- Orgovyx (relugolix; Sumitomo Pharma/Takeda)

PARP inhibitors

Marketed drugs
- Rubraca (rucaparib; Pharmaand GmbH)
- Lynparza (olaparib; AstraZeneca)
- Talzenna (talazoparib; Pfizer)
Pipeline drugs
- Saruparib (AstraZeneca)

PD-1/PD-L1 checkpoint inhibitors

Pipeline drugs
- Tecentriq (atezolizumab; Genentech/Roche)
- Keytruda (pembrolizumab; Merck & Co.)

Radiation-based therapies

Marketed drugs
- Xofigo (radium-223 dichloride; Bayer)
- Pluvicto (Lutetium-177 PSMA 617; Novartis)
Pipeline drugs
- [Lu-177]-PNT2002 (Lantheus/POINT Biopharma)

AKT inhibitors

Pipeline drugs
- Truqap (capivasertib; AstraZeneca)

Cyclin-dependent kinase inhibitors

Pipeline drugs
- Verzenio (abemaciclib; Eli Lilly and Company)

Future treatment trends

Key insights summary

Appendix

KOL details
- KOLs from North America
- KOLs from Europe